Federal Correctional Complex (FCC) Butner has 262 patients with diabetes who are followed in a pharmacist-led comprehensive diabetes management clinic. Patients enrolled in clinic are regularly seen by a pharmacist who can adjust diabetes medications and order relevant labs through a collaborative practice agreement. Newer diabetes technologies including continuous glucose monitoring (CGM) have become the standard of care for patients with diabetes on intensive insulin therapy. This technology allows for optimal blood glucose control and improved safety through reduced episodes of dangerous low blood glucose. In order to align with current standards of care, CGM devices were implemented at FCC Butner for patients in the pharmacy comprehensive diabetes management clinic. Several challenges were overcome for the successful implementation of these devices in a correctional setting. Approval through Information Technology and local authority had to be obtained due to security concerns with using this technology. Logistical challenges were also encountered, including device charging, sensor changes, and ordering of supplies. Before starting the use of this program, coordinated education for health services employees was provided, including on-site education from manufacturer partners. Support from institution leadership, including the Warden, was the final step to ensure that all those involved in overseeing care for our patient population were prepared for this new technology. Criteria were established to guide providers in offering this technology to certain patients. Those considered eligible for regular use of a “personal” CGM device included those with: type 1 diabetes, on multiple daily insulin injections, erratic blood glucose despite regular insulin adjustment and frequent hypoglycemia. Others on insulin therapy, with an elevated A1C, and difficulty in understanding glucose patterns are considered for “professional” CGM devices. This technology has assisted in determining better treatment recommendations, guiding medication adjustments for improved glucose control. Since the inception of the program on 1/1/23 there have been 111 patients who have received at least one CGM sensor application, of these 50 patients have been provided a personal CGM reader to aid in monitoring glucose values and providing alarms for low and high glucose excursions. These patients are followed closely in the pharmacy diabetes clinic with CGM data reviewed at each visit, assisting with adjustments to medications and providing focused lifestyle changes based on glucose patterns. Improvements in glycemic outcomes were evaluated. For those who had at least 1 sensor applied from 1/1/23 to 5/31/23, average A1C reduced from 9.6% to 8.4% and Glucose Management Index (GMI) from the CGM report reduced from 8.5% to 8.0%. Additionally, average time in range (TIR) (70 mg/dL – 180 mg/dL) also improved from 34.9% to 43.6%. This small subset of data has demonstrated benefits of integrating CGM in the correctional setting. It has been well received by patients and has been beneficial for providers. The success of this roll out has been key in obtaining support from national stakeholders to assist in integrating use of CGM devices throughout the Bureau of Prisons.